Selective inhibition of nuclear export: a promising approach in the shifting treatment paradigms for hematological neoplasms
出版年份 2022 全文链接
标题
Selective inhibition of nuclear export: a promising approach in the shifting treatment paradigms for hematological neoplasms
作者
关键词
-
出版物
LEUKEMIA
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-02-01
DOI
10.1038/s41375-021-01483-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia
- (2021) Janek S. Walker et al. Journal of Hematology & Oncology
- Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study
- (2021) Erlene K. Seymour et al. CLINICAL CANCER RESEARCH
- Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)
- (2020) David P. Steensma et al. BLOOD
- Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome
- (2020) Jennifer H. Cooperrider et al. BONE MARROW TRANSPLANTATION
- A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia
- (2020) Walter Fiedler et al. BRITISH JOURNAL OF HAEMATOLOGY
- Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial
- (2020) Justin Taylor et al. Lancet Haematology
- Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
- (2020) Nagesh Kalakonda et al. Lancet Haematology
- Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair
- (2020) Jithma P. Abeykoon et al. BLOOD
- Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
- (2019) Andrzej J. Jakubowiak et al. BRITISH JOURNAL OF HAEMATOLOGY
- Altered nuclear export signal recognition as a driver of oncogenesis
- (2019) Justin Taylor et al. Cancer Discovery
- Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer
- (2019) Rachel Sexton et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study
- (2019) Bhavana Bhatnagar et al. LEUKEMIA & LYMPHOMA
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
- (2019) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- 466PInterim results from trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumours
- (2019) J Wang et al. ANNALS OF ONCOLOGY
- Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study
- (2019) Deborah M. Stephens et al. BLOOD
- Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome
- (2019) Sangmin Lee et al. BLOOD
- Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas
- (2019) Andrew J. Yee et al. BLOOD
- Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia
- (2019) Kendra Sweet et al. CLINICAL CANCER RESEARCH
- XPO1 is a critical player for bortezomib resistance in multiple myeloma: A quantitative proteomic approach
- (2019) Venkatesh Chanukuppa et al. Journal of Proteomics
- Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia
- (2019) Szymon Klossowski et al. JOURNAL OF CLINICAL INVESTIGATION
- Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies
- (2019) Isha Kapoor et al. Cell Death & Disease
- Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience
- (2018) Chezi Ganzel et al. AMERICAN JOURNAL OF HEMATOLOGY
- Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma
- (2018) Ujjawal H. Gandhi et al. Clinical Lymphoma Myeloma & Leukemia
- Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial
- (2018) Weiguo Zhang et al. HAEMATOLOGICA
- Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma
- (2018) Dan T. Vogl et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients
- (2018) Jiayi Yu et al. Journal of Hematology & Oncology
- H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers
- (2018) Michael Seiler et al. NATURE MEDICINE
- Targeting the XPO1-dependent nuclear export of E2F7 reverses anthracycline resistance in head and neck squamous cell carcinomas
- (2018) Natalia Saenz-Ponce et al. Science Translational Medicine
- Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death
- (2018) Christian Argueta et al. Oncotarget
- Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial
- (2018) Weiguo Zhang et al. HAEMATOLOGICA
- Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma
- (2018) Abbey R. Sadowski et al. BMC Veterinary Research
- Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates
- (2018) Xiaorong Gu et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase 1 study of selinexor plus mitoxantrone, etoposide, and cytarabine in acute myeloid leukemia.
- (2018) Bhavana Bhatnagar et al. JOURNAL OF CLINICAL ONCOLOGY
- Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
- (2018) Nizar J. Bahlis et al. BLOOD
- XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy
- (2017) Vincent Camus et al. Journal of Hematology & Oncology
- Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1
- (2017) A Cosson et al. LEUKEMIA
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration
- (2017) Asfar S. Azmi et al. Oncotarget
- Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma
- (2016) Fabrice Jardin et al. AMERICAN JOURNAL OF HEMATOLOGY
- XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase II to the Nucleus
- (2016) P. Ranganathan et al. CLINICAL CANCER RESEARCH
- CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways
- (2016) Xuejiao Liu et al. Journal of Hematology & Oncology
- KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells
- (2016) J Etchin et al. LEUKEMIA
- XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma
- (2016) Joel G. Turner et al. Oncotarget
- Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia
- (2015) Z. A. Hing et al. BLOOD
- Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia
- (2015) P. Ranganathan et al. BLOOD
- Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study
- (2015) Lene Sofie Granfeldt Østgård et al. JOURNAL OF CLINICAL ONCOLOGY
- Nuclear export inhibitors avert progression in preclinical models of inflammatory demyelination
- (2015) Jeffery D Haines et al. NATURE NEUROSCIENCE
- Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185
- (2015) Yoko Tabe et al. PLoS One
- Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation
- (2014) R. F. Schlenk et al. BLOOD
- Clinical translation of nuclear export inhibitors in cancer
- (2014) William T. Senapedis et al. SEMINARS IN CANCER BIOLOGY
- Prognostic impact and targeting of CRM1 in acute myeloid leukemia
- (2013) K. Kojima et al. BLOOD
- The Oncogene eIF4E: Using Biochemical Insights to Target Cancer
- (2013) Martin Carroll et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
- (2013) Jesus San Miguel et al. LANCET ONCOLOGY
- Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276
- (2013) J Schmidt et al. LEUKEMIA
- CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications
- (2013) Y-T Tai et al. LEUKEMIA
- Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma
- (2012) Kejie Zhang et al. EXPERIMENTAL HEMATOLOGY
- Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma
- (2012) Christian Gisselbrecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Consensus Induced Fit Docking (cIFD): methodology, validation, and application to the discovery of novel Crm1 inhibitors
- (2012) Ori Kalid et al. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
- An allosteric mechanism to displace nuclear export cargo from CRM1 and RanGTP by RanBP1
- (2010) Masako Koyama et al. EMBO JOURNAL
- Anguinomycins and Derivatives: Total Syntheses, Modeling, and Biological Evaluation of the Inhibition of Nucleocytoplasmic Transport
- (2010) Simone Bonazzi et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- NES consensus redefined by structures of PKI-type and Rev-type nuclear export signals bound to CRM1
- (2010) Thomas Güttler et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Structural basis for leucine-rich nuclear export signal recognition by CRM1
- (2009) Xiuhua Dong et al. NATURE
- Structural basis for assembly and disassembly of the CRM1 nuclear export complex
- (2009) Xiuhua Dong et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer
- (2008) Aurelia Noske et al. CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now